Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benkert

Showing results (561-570 of 621) with videos related to

Pageof 63
Sort By:
Neurology(R) Neuroimmunology & Neuroinflammation|May 13, 2026
Serum Glial Fibrillary Acidic Protein and Retinal Neuronal Loss as Additive Prognostic Markers of Disability in Multiple SclerosisShaumiya Sellathurai, Kean Schoenholzer, Federico Burguet Villena, et al.
Multiple Sclerosis and Related Disorders|September 1, 2022
Serum glial fibrillary acidic protein correlates with retinal structural damage in aquaporin-4 antibody positive neuromyelitis optica spectrum disorderTing-Yi Lin, Patrick Schindler, Ulrike Grittner, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 5, 2025
Serum Neurofilament Light Chain as a Biomarker for CIDP Diagnosis, Severity, and Treatment OutcomeRafael Klimas, Felix Kohle, Lea Horstkemper, et al.
JAMA Neurology|August 13, 2019
Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 YearsEster Cantó, Christian Barro, Chao Zhao, et al.
Annals of Clinical and Translational Neurology|December 19, 2023
Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosisAhmed Abdelhak, Kai Antweiler, Markus C Kowarik, et al.
European Journal of Neurology|February 2, 2026
Neurofilament Light Chain Concentration in the Prediction of Treatment Response in Multiple SclerosisNahid Moradi, Sifat Sharmin, Charles B Malpas, et al.
Journal of Visualized Experiments : Jove|June 23, 2025
A High-Fidelity Porcine Model of Orthotopic Heart Transplantation Following Donation after Circulatory DeathKrish C Dewan, Abigail R Benkert, Alejandro A Lobo, et al.
Praxis|March 27, 2024
[Recommendations for the diagnostic and therapy of behavioural and psychological symptoms of dementia (BPSD)]Egemen Savaskan, Dan Georgescu, Stefanie Becker, et al.
The Lancet. Neurology|July 31, 2023
Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation studyAhmed Abdelhak, Franziska Petermeier, Pascal Benkert, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 29, 2023
Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosisNuria Cerdá-Fuertes, Marc Stoessel, Gintaras Mickeliunas, et al.
Pageof 63

Showing results (561-570 of 621) with videos related to

Sort By:
Pageof 63
Neurology(R) Neuroimmunology & Neuroinflammation|May 13, 2026
Serum Glial Fibrillary Acidic Protein and Retinal Neuronal Loss as Additive Prognostic Markers of Disability in Multiple SclerosisShaumiya Sellathurai, Kean Schoenholzer, Federico Burguet Villena, et al.
Multiple Sclerosis and Related Disorders|September 1, 2022
Serum glial fibrillary acidic protein correlates with retinal structural damage in aquaporin-4 antibody positive neuromyelitis optica spectrum disorderTing-Yi Lin, Patrick Schindler, Ulrike Grittner, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 5, 2025
Serum Neurofilament Light Chain as a Biomarker for CIDP Diagnosis, Severity, and Treatment OutcomeRafael Klimas, Felix Kohle, Lea Horstkemper, et al.
JAMA Neurology|August 13, 2019
Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 YearsEster Cantó, Christian Barro, Chao Zhao, et al.
Annals of Clinical and Translational Neurology|December 19, 2023
Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosisAhmed Abdelhak, Kai Antweiler, Markus C Kowarik, et al.
European Journal of Neurology|February 2, 2026
Neurofilament Light Chain Concentration in the Prediction of Treatment Response in Multiple SclerosisNahid Moradi, Sifat Sharmin, Charles B Malpas, et al.
Journal of Visualized Experiments : Jove|June 23, 2025
A High-Fidelity Porcine Model of Orthotopic Heart Transplantation Following Donation after Circulatory DeathKrish C Dewan, Abigail R Benkert, Alejandro A Lobo, et al.
Praxis|March 27, 2024
[Recommendations for the diagnostic and therapy of behavioural and psychological symptoms of dementia (BPSD)]Egemen Savaskan, Dan Georgescu, Stefanie Becker, et al.
The Lancet. Neurology|July 31, 2023
Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation studyAhmed Abdelhak, Franziska Petermeier, Pascal Benkert, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 29, 2023
Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosisNuria Cerdá-Fuertes, Marc Stoessel, Gintaras Mickeliunas, et al.
Pageof 63